Hematopoietic inhibition early in chemotherapy, vascular endothelial cell damage from tumor cell infiltration, and asparaginase‐associated coagulopathy [18, 29] are all high‐risk factors for bleeding during the induction remission phase. The gene discussed is ASPG; the disease is neoplasm.